Table 1 Distribution of patients with inactive and active Behçet’s disease, according to clinical manifestations and medication use
iBD (n = 31) (%) | aBD (n = 30) (%) | |||
|---|---|---|---|---|
Current | Previous | Current | Previous | |
Clinical manifestations | ||||
Oral ulcers | 0 | 31 (100) | 21 (70.0) | 30 (100) |
Genital ulcers | 0 | 28 (90.3) | 5 (16.7) | 24 (80.0) |
Anterior uveitis | 0 | 14 (45.2) | 11 (36.7) | 8 (26.7) |
Posterior uveitis | 0 | 10 (32.3) | 7 (23.3) | 11 (36.7) |
Other ocular manifestationsa | 0 | 5 (16.1) | 4 (13.3) | 5 (16.7) |
Pseudofolliculitis | 0 | 18 (58.1) | 6 (20.0) | 11 (36.7) |
Erythema nodosum | 0 | 15 (48.4) | 8 (26.7) | 14 (46.7) |
CNS | 0 | 7 (22.6) | 5 (16.7) | 5 (16.7) |
Gastrointestinal | 0 | 2 (6.5) | 0 | 1 (3.3) |
Cardiovascular | 0 | 5 (16.1) | 3 (10.0) | 4 (13.3) |
Pathergy | 5 (16.1) | 2 (6.7) | ||
Othersb | 0 | 13 (41.9) | 5 (16.7) | 9 (30.0) |
Disease duration, years, median/minimum–maximum | 9/1 – 30 | 6/0 – 19 | ||
Age at BD onset, years, mean (SD) | 30.1 ± 9.6 | 28.7 ± 12.0 | ||
sBR-BDCAF, median/minimum–maximum | 0/0 – 0 | 3/2 – 4 | ||
Medications | 26 (83.9) | 29 (93.5) | 28 (93.3) | 23 (76.7) |
Colchicine | 14 (45.2) | 11 (35.5) | 15 (50.0) | 5 (16.7) |
Azathioprine | 14 (45.2) | 10 (32.5) | 16 (53.3) | 4 (13.3) |
Thalidomide | 2 (6.5) | 7 (22.6) | 3 (10.0) | 3 (10.0) |
Methotrexate | 3 (9.7) | 6 (19.4) | 1 (3.3) | 3 (10.0) |
Cyclophosphamide | 0* | 7 (22.6) | 5 (16.7)c | 2 (6.7) |
Penicillin G benzathine | 4 (12.9) | 7 (22.6) | 4 (13.3) | 4 (13.3) |
Anti-TNF | 5 (16.1) | 0 | 1 (3.3) | 1 (3.3) |
Corticosteroids | ||||
High dose | 5 (16.1)d | 13 (41.9) | 15 (50.0)d | 12 (40.0) |
Low dose | 5 (16.1) | 18 (58.1) | 6 (20.0) | 10 (33.3) |
Cyclosporine | 1 (3.2) | 6 (19.4) | 6 (20.0) | 5 (16.7) |
Pentoxifylline | 2 (6.5) | 2 (6.5) | 1 (3.3) | 2 (6.7) |
Minocycline | 0 | 3 (9.7) | 0 | 0 |
Dapsone | 0 | 0 | 0 | 1 (3.3) |
Chlorambucil | 0 | 2 (6.5) | 0 | 1 (3.3) |
Sulfasalazine | 0 | 1 (3.2) | 0 | 0 |